On May 22, 2025 Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, reported it will present data from its Phase 1 KisMET-01 study evaluating its investigational cMET-targeting ADC, MYTX-011, in patients with non-small cell lung cancer (NSCLC) at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Mythic Therapeutics, MAY 22, 2025, https://mythictx.com/2025/05/22/mythic-therapeutics-to-present-compelling-efficacy-data-from-phase-1-kismet-01-study-supporting-best-in-class-potential-of-investigational-cmet-adc-mytx-011-in-non-small-cell-lung-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=mythic-therapeutics-to-present-compelling-efficacy-data-from-phase-1-kismet-01-study-supporting-best-in-class-potential-of-investigational-cmet-adc-mytx-011-in-non-small-cell-lung-cancer [SID1234653310]). The presentation, which includes an updated data cut as of April 24, 2025, is the first disclosure of efficacy data for MYTX-011, demonstrating meaningful anti-tumor activity in cMET+ NSCLC across cMET levels, histologies, and actionable genetic alterations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Abstract Title: MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.
Presenter: Rebecca Heist, M.D., M.P.H., Medical Oncologist, Massachusetts General Hospital, Cancer Center
Format: Poster Session
Session Name: Lung Cancer – Non-Small Cell Metastatic
Session Date and Time: Saturday, May 31, 2025, at 1:30 – 4:30 PM CDT
Poster Board Number: 93
Abstract Number: 8613
About KisMET-01
KisMET-01 (NCT05652868) is a multicenter, first-in-human Phase 1 study of MYTX-011 in patients with previously treated, locally advanced or metastatic NSCLC. The study is comprised of two parts: dose escalation (Part 1) in patients with NSCLC of any histology of cMET expression with cMET analyzed whenever tumor tissue is available, followed by dose expansion (Part 2) in cMET-positive (cMET+) patients selected by immunohistochemistry (Ventana SP44). cMET levels are defined as high (≥50% tumor cells with 3+ staining), intermediate (≥25% and <50% with 3+ staining), low (≥25% with 2+ staining, excluding high and intermediate), and ultra-low (≥75% excluding high, intermediate, and low).
About MYTX-011
MYTX-011 is an investigational cMET-targeting ADC, which leverages Mythic’s innovative FateControl technology. FateControl ADCs are pH engineered to unbind their target after internalization, intended to improve both tumor uptake and drug exposure for improved safety, tolerability and efficacy. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).